447 related articles for article (PubMed ID: 20720058)
21. Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma.
Maruoka Y; Abe K; Baba S; Isoda T; Sawamoto H; Tanabe Y; Sasaki M; Honda H
Radiology; 2012 Dec; 265(3):902-9. PubMed ID: 23012466
[TBL] [Abstract][Full Text] [Related]
22. SPECT/CT imaging in children with papillary thyroid carcinoma.
Kim HY; Gelfand MJ; Sharp SE
Pediatr Radiol; 2011 Aug; 41(8):1008-12. PubMed ID: 21607603
[TBL] [Abstract][Full Text] [Related]
23. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
24. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans.
Ma C; Wang X; Shao M; Zhao L; Jiawei X; Wu Z; Wang H
Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):220-7. PubMed ID: 24844253
[TBL] [Abstract][Full Text] [Related]
25. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
26. The prevalence of thyroglossal tract thyroid tissue on SPECT/CT following (131) I ablation therapy after total thyroidectomy for thyroid cancer.
Barber TW; Cherk MH; Topliss DJ; Serpell JW; Yap KS; Bailey M; Kalff V
Clin Endocrinol (Oxf); 2014 Aug; 81(2):266-70. PubMed ID: 24483626
[TBL] [Abstract][Full Text] [Related]
27. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
Shammas A; Degirmenci B; Mountz JM; McCook BM; Branstetter B; Bencherif B; Joyce JM; Carty SE; Kuffner HA; Avril N
J Nucl Med; 2007 Feb; 48(2):221-6. PubMed ID: 17268018
[TBL] [Abstract][Full Text] [Related]
28. Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer.
Seiboth L; Van Nostrand D; Wartofsky L; Ousman Y; Jonklaas J; Butler C; Atkins F; Burman K
Thyroid; 2008 Feb; 18(2):103-11. PubMed ID: 18279011
[TBL] [Abstract][Full Text] [Related]
29. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants.
Bajén MT; Mañé S; Muñoz A; García JR
J Nucl Med; 2000 Dec; 41(12):2038-42. PubMed ID: 11138690
[TBL] [Abstract][Full Text] [Related]
30. 131I SPECT/CT in the follow-up of patients with differentiated thyroid carcinoma.
Menges M; Uder M; Kuwert T; Schmidt D
Clin Nucl Med; 2012 Jun; 37(6):555-60. PubMed ID: 22614186
[TBL] [Abstract][Full Text] [Related]
31. Utility of Adding SPECT/CT Imaging to Post-Therapeutic Radioiodine Whole-Body Scan in Patients with Differentiated Thyroid Cancer.
Sriprapaporn J; Sethanandha C; Yingsa-nga T; Komoltri C; Thongpraparn T; Harnnanthawiwai C
J Med Assoc Thai; 2015 Jun; 98(6):596-605. PubMed ID: 26219165
[TBL] [Abstract][Full Text] [Related]
32. [Impact of 131I SPECT/CT on the management of differentiated thyroid carcinoma outpatients with radioablation].
Mizokami D; Kosuda S; Shiotani A; Kinoshita F; Saotome K; Morozumi K
Nihon Jibiinkoka Gakkai Kaiho; 2014 May; 117(5):673-80. PubMed ID: 24956745
[TBL] [Abstract][Full Text] [Related]
33. Frequent visualization of thyroglossal duct remnant on post-ablation 131I-SPECT/CT and its clinical implications.
Lee M; Lee YK; Jeon TJ; Chang HS; Kim BW; Lee YS; Park CS; Ryu YH
Clin Radiol; 2015 Jun; 70(6):638-43. PubMed ID: 25824279
[TBL] [Abstract][Full Text] [Related]
34. Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy.
Seabold JE; Gurll N; Schurrer ME; Aktay R; Kirchner PT
J Nucl Med; 1999 Sep; 40(9):1434-40. PubMed ID: 10492361
[TBL] [Abstract][Full Text] [Related]
35. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of SPECT/CT for equivocal findings on (131)I whole-body scan in a patient with differentiated papillary thyroid cancer.
Choi B; Kim DH; Son SH; Zeon S; Ahn BC
Clin Nucl Med; 2014 Feb; 39(2):e160-2. PubMed ID: 23531738
[TBL] [Abstract][Full Text] [Related]
37. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
38. Role of [
Xu Q; Liu R; Wang J; Huang Y; Li S; Zhang L; Wang F
Nucl Med Biol; 2020; 88-89():34-43. PubMed ID: 32688289
[TBL] [Abstract][Full Text] [Related]
39. The value of I-131 SPECT in the detection of recurrent differentiated thyroid cancer.
Geerlings JA; van Zuijlen A; Lohmann EM; Smit JW; Stokkel MP
Nucl Med Commun; 2010 May; 31(5):417-22. PubMed ID: 20154638
[TBL] [Abstract][Full Text] [Related]
40. Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid cancer.
Campennì A; Violi MA; Ruggeri RM; Sindoni A; Moleti M; Vermiglio F; Baldari S
Nucl Med Commun; 2010 Apr; 31(4):274-9. PubMed ID: 20087239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
